Importantly, this heterogeneity can have profound consequences for therapy response; when patients eventually acquire resistance to MAPK inhibitors, > 50% of resistant tumours show enrichment for AXL‐high populations (Tirosh et al, 2016). The gene discussed is AXL; the disease is neoplasm.